



Treatment Action Group



TUBERCULOSIS RESEARCH  
AND DEVELOPMENT:

# 2013 Report on Tuberculosis Research Funding Trends, 2005-2012



## 2005–2012 NIH Funding for Select Infectious Diseases (in Millions)

	2005	2006	2007	2008	2009*	2010*	2011	2012
HIV/AIDS	\$2,921	\$2,902	\$2,906	\$2,928	\$3,338	\$3,407	\$3,059	\$3,074
Smallpox	\$187	\$149	\$142	\$94	\$98	\$97	\$41	\$40
Anthrax	\$183	\$150	\$160	\$134	\$115	\$130	\$87	\$84
Tuberculosis	\$158	\$150	\$188	\$142	\$216	\$224	\$209	\$218
Malaria	\$104	\$98	\$112	\$142	\$121	\$148	\$145	\$152


\* Includes ARRA stimulus funds

National Institutes of Health (U.S.). Estimates of funding for various research, condition, and disease categories. Available from: [http://report.nih.gov/categorical\\_spending.aspx](http://report.nih.gov/categorical_spending.aspx). (Accessed 2 October 2013)


## Summary of Changes in TB R&D Investment, 2005–2012

Year	Total TB R&D Investment	Change over Previous Year	Change over Previous Year	Change over 2005	Change over 2005
2005	\$357,426,121				
2006	\$417,824,708	\$60,398,587	16.9%	\$60,398,587	16.9%
2007	\$473,920,682	\$56,095,974	13.4%	\$116,494,561	32.6%
2008	\$491,476,917	\$17,556,235	3.7%	\$134,050,796	37.5%
2009	\$619,209,536	\$127,732,619	26.0%	\$261,783,415	73.2%
2010	\$630,446,462	\$11,236,926	1.8%	\$273,020,341	76.4%
2011	\$657,815,332	\$27,368,870	4.3%	\$300,389,211	84.0%
2012	\$627,389,725	-\$30,425,607	-4.6%	\$269,963,604	75.5%

# Annual Global Plan Research Funding Targets versus 2012 Investments




## Total TB R&D Funding: 2005–2012




# TB R&D Funding by Donor Sector: 2012

Total: \$627,389,725



## Total TB R&D Funding by Donor Sector: 2005–2012




	Public*	Philanthropy	Private	Multilateral
2005	\$234,503,645	\$78,178,708	\$43,095,353	\$1,648,083
2006	\$246,862,858	\$116,289,274	\$53,138,347	\$1,534,259
2007	\$272,404,317	\$132,326,981	\$69,387,383	NA
2008	\$264,944,215	\$154,513,987	\$72,018,715	NA
2009	\$395,326,911	\$123,383,703	\$99,973,537	\$525,385
2010	\$376,199,816	\$123,974,117	\$124,249,938	\$6,022,590
2011	\$387,307,078	\$123,889,768	\$144,972,421	\$1,646,064
2012	\$378,572,425	\$127,730,076	\$112,927,490	\$8,159,734

\* Includes funding from international development agencies  
 NA = Not available


# TB R&D Investments by Research Category: 2012

Total: \$627,389,725







## Investments in TB R&D by Research Category: 2005–2012




# Basic Science: \$129,623,072




# TB Diagnostics: \$42,429,160




# TB Drugs: \$237,815,172




# TB Vaccines: \$86,558,192



# Operational Research: \$77,128,668



## TB R&D PDPs and Research Consortia: 2005–2012



	Aerias	CREATE	FIND	TB Alliance	TBVAC	TDR	TBVI	OETC	EDCTP	NM4TB	MM4TB
2005	\$18,580,139	\$10,000,000	\$6,778,239	\$7,874,983	\$5,445,450	N/A	N/A	N/A	N/A	N/A	N/A
2006	\$25,923,809	\$8,298,826	\$5,492,942	\$14,808,362	\$4,451,895	\$2,995,748	N/A	N/A	\$580,039	\$2,214,000	N/A
2007	\$37,704,051	\$12,375,000	\$1,145,409	\$22,624,182	\$6,091,335	\$453,382	N/A	N/A	\$805,625	\$2,214,000	N/A
2008	\$48,679,266	\$18,493,585	\$14,177,202	\$26,885,734	\$3,944,425	\$3,817,352	\$339,741	\$1,196,000	\$1,416,064	\$2,214,000	N/A
2009	\$50,792,515	\$12,786,985	\$9,975,320	\$35,643,490	\$5,634,040	\$4,243,264	\$841,333	\$2,851,000	\$10,343,479	\$2,214,000	N/A
2010	\$41,572,980	\$5,410,545	\$8,212,896	\$37,538,794	Concluded	\$3,900,000	\$3,700,914	\$7,142,159	\$9,081,799	\$2,214,000	N/A
2011	\$38,166,117	\$2,657,411	\$13,938,587	\$27,824,033	Concluded	\$1,315,700	\$4,731,422	\$4,568,160	\$12,313,115	Concluded	\$4,644,099
2012	\$38,904,315	Concluded	\$5,726,157	\$34,388,929	Concluded	NA	\$3,434,338	\$4,157,360	\$11,393,907	Concluded	\$3,086,837

TDR = WHO Special Programme for Research and Training in Tropical Diseases; OETC = Oxford-Emergent Tuberculosis Consortium;


NM4TB = New Medicines for Tuberculosis; MM4TB = More Medicines for Tuberculosis

N/A = Not applicable; NA = Not available






### Historical Data on TB R&D Funders Ranked 13–24 that Invested above \$500,000 in 2012




### Historical Data on TB R&D Funders Ranked 25–35 that Invested above \$500,000 in 2012





### Historical Data on TB R&D Funders Ranked 50–62 that Invested Less than \$500,000 in 2012





## TB R&D Funders Unresponsive in 2012

Anacor

Belgian Federal Science Policy Office

Brazilian Ministry of Health, National TB Program

Brazilian Ministry of Health, Department of Science and Technology

British Council

Canada University Health Network

Chinese Center for Disease Control and Prevention

Consejo Nacional de Ciencia y Tecnología

Dafra Pharma

Damien Foundation

Japan BCG Laboratory

Japan International Cooperation Agency Japanese Ministry of Health, Labour and Welfare

Norwegian Ministry of Health and Care Services

PepsiCo

Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association

Rockefeller Foundation

South African Medical Research Council

Thailand National Science and Technology Development Agency

U.K. Department of Health

U.K. Health Protection Agency/National Institute for Health Research